Decitabine Enhances Vγ9Vδ2 T Cell-Mediated Cytotoxic Effects on Osteosarcoma Cells via the NKG2DL–NKG2D Axis

Regulatory functions of γδ T cells

(2018) Christian Peters et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Effects of 5-Aza-2′-deoxycytidine (decitabine) on gene expression

(2018) Ratnam S. Seelan et al.   DRUG METABOLISM REVIEWS

Butyrophilin3A proteins and Vγ9Vδ2 T cell activation

(2018) Siyi Gu et al.   SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY

Current and future therapeutic approaches for osteosarcoma

(2017) Douglas J. Harrison et al.   Expert Review of Anticancer Therapy

DNA Methylation Mediated Down-Regulation of miR-370 Regulates Cell Growth through Activation of the Wnt/β-Catenin Signaling Pathway in Human Osteosarcoma Cells

(2017) Wentao Zhang et al.   International Journal of Biological Sciences

The Ambiguous Role of γδ T Lymphocytes in Antitumor Immunity

(2017) Guranda Chitadze et al.   TRENDS IN IMMUNOLOGY

MET/SMAD3/SNAIL circuit mediated by miR-323a-3p is involved in regulating epithelial–mesenchymal transition progression in bladder cancer

(2017) Jiangfeng Li et al.   Cell Death & Disease

Zoledronic acid sensitizes rhabdomyosarcoma cells to cytolysis mediated by human γδ T cells

(2017) Ling‑Ling Sun et al.   Oncology Letters

Zoledronate can induce colorectal cancer microenvironment expressing BTN3A1 to stimulate effector γδ T cells with antitumor activity

(2017) Maria Raffaella Zocchi et al.   OncoImmunology

BTN3A is a prognosis marker and a promising target for Vγ9Vδ2 T cells based-immunotherapy in pancreatic ductal adenocarcinoma (PDAC)

(2017) Audrey Benyamine et al.   OncoImmunology

Effect of entinostat on NK cell-mediated cytotoxicity against osteosarcoma cells and osteosarcoma lung metastasis

(2017) Simin Kiany et al.   OncoImmunology

Decitabine enhances anti-CD33 monoclonal antibody BI 836858-mediated natural killer ADCC against AML blasts

(2016) S. Vasu et al.   BLOOD

Regulatory and effector functions of gamma-delta (γδ) T cells and their therapeutic potential in adoptive cellular therapy for cancer

(2016) Sourav Paul et al.   INTERNATIONAL JOURNAL OF CANCER

IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression

(2016) Xiaoran Zhang et al.   NEURO-ONCOLOGY

T-Cell-Based Immunotherapy for Osteosarcoma: Challenges and Opportunities

(2016) Zhan Wang et al.   Frontiers in Immunology

BTN3A molecules considerably improve Vγ9Vδ2T cells-based immunotherapy in acute myeloid leukemia

(2016) Audrey Benyamine et al.   OncoImmunology

A phase I trial combining decitabine/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma

(2015) Deepa K. Krishnadas et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Activated and expanded natural killer cells target osteosarcoma tumor initiating cells in an NKG2D–NKG2DL dependent manner

(2015) L. Fernández et al.   CANCER LETTERS

Trastuzumab enhanced the cytotoxicity of Vγ9Vδ2 T cells against zoledronate-sensitized osteosarcoma cells

(2015) Meng Liu et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Osteosarcoma: Current Treatment and a Collaborative Pathway to Success

(2015) Michael S. Isakoff et al.   JOURNAL OF CLINICAL ONCOLOGY

γδ T cells and epigenetic drugs: A useful merger in cancer immunotherapy?

(2015) Jaydeep Bhat et al.   OncoImmunology

Induction of a specific CD8+ T-cell response to cancer/testis antigens by demethylating pre-treatment against osteosarcoma

(2015) Binghao Li et al.   Oncotarget

Decitabine-Induced Demethylation of 5′ CpG Island in GADD45A Leads to Apoptosis in Osteosarcoma Cells

(2015) Khaldoun Al-Romaih et al.   NEOPLASIA

Decitabine, a new star in epigenetic therapy: the clinical application and biological mechanism in solid tumors

(2014) Jing Nie et al.   CANCER LETTERS

Decitabine facilitates immune recognition of sarcoma cells by upregulating CT antigens, MHC molecules, and ICAM-1

(2014) Deepa Kolaseri Krishnadas et al.   TUMOR BIOLOGY

Clinical Applications of Gamma Delta T Cells with Multivalent Immunity

(2014) Drew C. Deniger et al.   Frontiers in Immunology

γδ T cells for cancer immunotherapy

(2014) Jonathan PH Fisher et al.   OncoImmunology

Comparison of γδ T cell responses and farnesyl diphosphate synthase inhibition in tumor cells pretreated with zoledronic acid

(2013) Atif S. M. Idrees et al.   CANCER SCIENCE

Tumor-Derived    Regulatory T Cells Suppress Innate and Adaptive Immunity through the Induction of Immunosenescence

(2013) J. Ye et al.   JOURNAL OF IMMUNOLOGY

Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents

(2013) H Yang et al.   LEUKEMIA

Tumor-promoting Versus Tumor-antagonizing Roles of γδ T Cells in Cancer Immunotherapy

(2012) Volker Kunzmann et al.   JOURNAL OF IMMUNOTHERAPY

Zoledronic Acid Produces Antitumor Effects on Mesothelioma Through Apoptosis and S-Phase Arrest in p53-Independent and Ras prenylation-Independent Manners

(2012) Shinya Okamoto et al.   Journal of Thoracic Oncology

Clinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumours

(2011) A J Nicol et al.   BRITISH JOURNAL OF CANCER

Phase I/II study of adoptive transfer of γδ T cells in combination with zoledronic acid and IL-2 to patients with advanced renal cell carcinoma

(2011) Hirohito Kobayashi et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Improving T-cell Therapy for Relapsed EBV-Negative Hodgkin Lymphoma by Targeting Upregulated MAGE-A4

(2011) C. R. Cruz et al.   CLINICAL CANCER RESEARCH

A 5-aza-2'-deoxycytidine/valproate combination induces cytotoxic T-cell response against mesothelioma

(2011) S. Leclercq et al.   EUROPEAN RESPIRATORY JOURNAL

IFN-γ enhances HOS and U2OS cell lines susceptibility to γδ T cell-mediated killing through the Fas/Fas ligand pathway

(2011) Zhaoxu Li et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Induction of MHC class I-related chain B (MICB) by 5-aza-2′-deoxycytidine

(2008) Kai-Fu Tang et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Apoptosis of CD4+CD25high T cells in response to Sirolimus requires activation of T cell receptor and is modulated by IL-2

(2008) Kerrington R. Molhoek et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY